Form 4: Theravance Biopharma Executive Sells Shares

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, sold 13,314 ordinary shares via a 10b5-1 plan.

Summary

• Rhonda Farnum, SVP of Commercial & Medical Affairs, disposed of 13,314 ordinary shares of Theravance Biopharma (TBPH).
• The shares were sold in multiple transactions on June 15, 2026, at a weighted average price ranging between $16.38 and $16.39 per share.
• Following these transactions, the reporting person retains beneficial ownership of 232,457 ordinary shares.
• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan dated September 3, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is a standard administrative procedure for executives.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading based on material non-public information.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Continued selling by insiders may be perceived negatively by the market, potentially impacting short-term share price sentiment.

Future Outlook

No forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as non-indicative of company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives in the biotechnology sector to ensure compliance with SEC regulations while liquidating equity holdings.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Equity Sale, Biotech